We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Elevated Heat Shock Protein Linked to Cancer Prognosis

By LabMedica International staff writers
Posted on 15 Nov 2011
Patients whose estrogen receptor (ER)-positive breast cancers have high levels of the heat shock factor 1 (HSF1) experience poor outcomes including increased mortality. More...


Patient prognoses can vary widely although ER-positive breast cancers are often associated with better outcomes than other breast cancer-tumor types, including those that are negative for the Human Epidermal growth factor Receptor (HER-2) receptor and so-called triple negative breast cancers.

Scientists at the Whitehead Institute of Biomedical Research (Cambridge, MA, USA) collaborating with others, examined HSF1 levels in breast cancer tissue samples from 1,841 participants in one of the largest and longest-running epidemiological studies of women's health. They looked at the relationship between HSF1 status, using tissue microarrays and immunohistochemical staining of paraffin blocks, and the participants' outcomes.

Compared with ER-positive breast cancer patients with low levels of HSF1, those with high levels of HSF1 had a poorer outcome, including increased mortality. The investigators also noted that invasive ER-positive tumors with elevated HSF1 levels tended to be larger and more aggressive than those with normal HSF1 levels did. The heat shock response, which is controlled by transcription factors like HSF1, enables cells to withstand temperature spikes and other stressors. Cancer cells are deviants that live in a tumor's milieu, which lacks abundant nutrients and oxygen, but is crammed with distorted and abnormal proteins. To survive these exceptionally stressful circumstances, many cancer cells have usurped the normally beneficial heat shock response to support their existence.

Because of this strong link between HSF1 concentrations and prognosis, HSF1 testing could become a valuable part of the oncologist's toolkit. Sandro Santagata, MD, PhD, lead author and an instructor in pathology at Brigham and Women's Hospital (Boston, MA, USA) said, "If HSF1 status can help predict which of the ER-positive patients will do well with standard treatments and which ones won't, that would be really helpful. In terms of understanding the biology, we think these findings are really important for reinforcing our interest in pursuing the heat shock response itself as a therapeutic target." The study was published October 31, 2011 in the Proceedings of the National Academy of Sciences of the United States (PNAS).

Related Links:
Whitehead Institute of Biomedical Research
Brigham and Women's Hospital


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.